CRISPR Therapeutics (CRSP) to Release Quarterly Earnings on Wednesday

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 14th. Analysts expect CRISPR Therapeutics to post earnings of ($1.26) per share for the quarter.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same quarter in the prior year, the company posted ($1.43) EPS. The business's revenue was up 71.6% on a year-over-year basis. On average, analysts expect CRISPR Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP traded up $2.16 during mid-day trading on Monday, reaching $37.78. 937,348 shares of the company's stock were exchanged, compared to its average volume of 1,666,673. The firm has a market capitalization of $3.26 billion, a PE ratio of -8.63 and a beta of 1.88. CRISPR Therapeutics has a one year low of $30.04 and a one year high of $67.88. The business's fifty day simple moving average is $38.15 and its two-hundred day simple moving average is $42.71.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Truist Financial lifted their price target on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a research note on Wednesday, February 12th. HC Wainwright reiterated a "buy" rating and set a $65.00 price target on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Royal Bank of Canada reduced their price objective on CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a research report on Wednesday, February 12th. JMP Securities reiterated a "market outperform" rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Finally, Evercore ISI upgraded CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and boosted their price target for the stock from $60.00 to $99.00 in a report on Friday, February 14th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, CRISPR Therapeutics has a consensus rating of "Hold" and an average target price of $71.75.

Insider Buying and Selling at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 1,198 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the transaction, the chief operating officer now owns 8,263 shares of the company's stock, valued at approximately $350,516.46. The trade was a 12.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares in the company, valued at $9,473,037.60. This trade represents a 9.66% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,381 shares of company stock valued at $1,608,243. Company insiders own 4.30% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.